Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $55.25 | Total: $276.25 |
| 1 | 10 | $46.80 | Total: $468.00 |
| 1 | 25 | $39.65 | Total: $991.25 |
| 1 | 50 | $33.80 | Total: $1,690.00 |
| 1 | 100 | $29.25 | Total: $2,925.00 |
Overview
Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease.
Chemical Properties
| Molecular Formula | C6H8CuN3O2 |
| Molecular Weight | 217.69 |
| CAS Numbers | 77280-83-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1[O-][Cu+2]2[N]3(C(C[C@@]1([NH2]2)[H])=CN=C3)[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Kroepfl T, et al. Copper concentration of liver tissue under long-term copper-histidine therapy in a patient with Menkes disease. J Inherit Metab Dis. 2006;29[4] 593.